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to-voxel mapping between the initial planning scan and the 
treatment scan. Therefore, deformation maps can be applied 
to propagate contours from planning CT to daily images, but 
also to compute dose distribution from the deformed images 
for dose accumulation purpose.  
In this presentation, we will describe the general framework 
of deformable image registration, and will cover the main 
class-solutions for registration-based recontouring according 
to the tumor location and the available imaging modality, 
i.e. kV- or MV/CB-CT. Typical adaptive workflows based on 
deformable registration will be presented, as well as their 
advantages and potential limitations. Last, we will emphasize 
the essential role of the operator for accuracy and 
consistency check of the deformed contours, any inaccuracy 
in this step necessarily introducing systematic errors in the 
planning process.  
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In the Erasmus MC radiotherapy department, atlas-based 
auto-segmentation of both clinical target volumes and organs 
at risk (OARs) is an important time-saving tool in daily clinical 
routine to assist both physicians and technicians. The 
accuracy of delineations has become increasingly important 
due to enhanced conformality of dose distributions as 
realized by IMRT and VMAT, and the use of reduced PTV 
margins in combination with image guidance. Clinical 
validation of atlas-based auto-segmentation for head-and-
neck patients showed a reduction of hands-on time for 
delineation from 180 to 66 minutes, where structures were 
evaluated as ‘minor-deviations, editable’ or better (D. Teguh 
; Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 4, pp. 
950–957, 2011). The influence of geometric differences 
between autocontours and manual delineations by different 
observers on the dosimetric impact can differ for CTV and for 
OAR (Voet PW, Radiother. Oncol. 2011 Mar;98(3):373-7). We 
clinically implemented Admire (Elekta AB, Sweden) as part of 
our workflow in 2010. In this workflow, critical review and 
editing of the autocontours is still relevant.  
For several target sites, a database was created containing 
fully contoured reference CT data sets (atlases). Depending 
on the tumor site, one or more atlases are used as an input 
for the generation of the patient-specific delineation (using 
the staple algorithm). The strategy of a single atlas can 
particularly be useful in case of adaptive treatments, 
resulting in a quick and more accurate autocontouring using 
the original delineated patient CT as the only atlas. An 
overview of the clinical implementation of Admire with 
regard to several tumor sites and the relation to treatment 
techniques such as breath-hold will be presented. 
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Purpose or Objective: Preoperative level of CA 19-9 
(prCA19.9) predicts survival of patients (pts) undergoing 
surgery for pancreatic adenocarcinoma (PAC). Actually, there 
is no evidence of using prCA19.9 as a marker customizing and 
modulating effectiveness of adjuvant treatment or predicting 
pattern of failure. Therefore, the purpose of this pooled 
analysis was to determine whether prCA19.9 could predict 
overall survival (OS), local control (LC), disease metastasis 
free survival (DMFS) and evaluate effectiveness of adjuvant 
therapies in a broad population. 
 
Material and Methods: We performed a multicenter 
retrospective analysis of 1122 patients (pts) who underwent 
surgical resection +/- adjuvant treatment [chemotherapy 
(aCT), radiotherapy +/- concomitant CT (RCT)] for PAC 
between 2000 and 2014 from 8 different institutions. Among 
700 pts with prCA19.9 value we applied the Kaplan-Meier 
method and the log-rank test to investigate differences in 
OS, LC, DMFS between defined groups based on: clinical and 
pathological factors, 4 prCA19.9 cutoff (5, 37, 100, 353) and 
5 relative prCa19.9 classes (0.0-5.0, 5.1-37.0, 37.1-100, 
100.1-353.0, >353.1). We fitted Weibull regression model 
with shared frailty on institution to identify independent 
predictors of OS using data from 404 pts with complete 
information. We applied a backward stepwise strategy to 
select the covariates, forcing CRT and RT in the final model. 
 
Results: Median follow-up (FU) was 27 months (2-225). At 
univariate analysis there was a strong impact of prCA19.9 
classes (0.0-5.0, 5.1-37.0, 37.1-100, 100.1-353.0, >353.1) on 
5-years OS (5.7% vs 37.9 vs 27.1 vs 17.4 vs 10.9, p< 0.001, 
Figure 1), 5-years LC (47.2% vs 63.3% vs 59.4% vs 43.4% vs 
50.2%, p= 0.008), 5-years DMFS (17.0% vs 46.0% vs 39.0% vs 
26.7 vs 23.4, p<0.001), respectively. Only in pts with prCA 
19.9 > 353.1 U/ml aCT had positive impact on 5-year OS 
(47.4% in pts treated with aCT vs 30.2% in pts not treated 
with aCT, p= 0.006). At multivariable model, sub-analysis of 
404 pts showed (Table 1): worse OS for grading 3 tumor (HR: 
1.85 95%CI 1.26-2.70, p= 0.002) tumor diameter > 30 mm 
(HR: 1.85, 95%CI: 1.35-2.53, p< 0.001), and better OS for pts 
treated with RCT doses > 50 Gy (HR: 0.38, 95%CI: 0.23-0.63, 
p< 0.001). Median OS worsened in pts with prCA19.9 >100 and 
<353 (HR: 1.77, 95%CI: 1.23-2.56, p= 0.002) and in pts with 
prCA19.9 ≥353.1 (HR: 1.92, 95%CI: 1.34-2.76, p<0.001). 
 
